Guidance

PCV risk groups: patient group direction template

Patient group direction (PGD) template to support the provision of PCV13 vaccine to individuals with underlying medical conditions.

• From: UK Health Security Agency
• Published: 1 March 2017
• Last updated: 29 January 2025 — See all updates

Applies to England

Documents

PCV risk groups: PGD template

Ref: UKHSA gateway number GOV-17863

MS Word Document, 223 KB

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@phe.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This PGD template supports the provision of pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) (PCV13) to individuals with underlying medical conditions.

The PCV Risk Groups PGD version 6.0 is valid from 28 February 2025 to 31 May 2027.

Practitioners must not use this PGD template until it has been authorised in Section 2. This is a legal requirement see Human Medicines Regulations 2012. Practitioners should follow local policy/procedures to access authorised PGD documents.

This PGD template should be used with reference to current national guidance, the Green Book, and Summary of Product Characteristics.

Published 1 March 2017
Last updated 29 January 2025 + show all updates

1. 29 January 2025

   Added version 6.0 – see page 3 for change history.

2. 30 January 2024

   Added notice of extension.

3. 17 February 2022

   Added v05.00 – see page 2 for change history.

4. 28 January 2020

   Updated with V04.00 document.

5. 30 April 2019

   Added version V03.00 - routine review of PGD prior to expiry.

6. 26 May 2017

   Version 2. Updated PGD dose section in line with revised pneumococcal Green Book chapter and refined inclusion criteria.

7. 1 March 2017

   First published.